探討蛋白質沉澱劑對自萃取雞冠玻尿酸最適條件之探討

林曉億、陳明造

E-mail: 9707199@mail.dyu.edu.tw

摘 要

玻尿酸是體內的多醣類高分子聚合物，具有親水性與黏彈性，其製備方法有二種：一是由動物組織中萃取，主要來源是人類臍帶、雞冠和牛眼玻璃體等；二是微生物醱酵方法，主要是存在鏈球菌(streptococci)莢膜中。在業界所選用的原料中，以雞冠為主要來源，經萃取及純化後而得，但在純化過程常用到氯仿去除雜質，而氯仿屬於列管中化學毒性物質，具有毒性高、單價高的缺點。故本篇論文主要以不同的蛋白質沉澱劑列出作為變因，找出是否有其他試劑可以取代目前常用的物質，並探討純化後產品之產率及物理性質。結果顯示控制組所得到玻尿酸產率為0.661%、純度為每克粗萃取物中含有0.201 mg的玻尿酸、黏度為5.04 cps、蛋白質含量為0.064 mg/mL，由上述結果得知控制組純化出的玻尿酸產物其物性和氯仿有相似的結果，故控制組用來取代氯仿，不但可以節省成本還可達到減少環境污染之效果。

關鍵詞 : 玻尿酸;去蛋白劑;蛋白質沉澱

目錄

參考文獻

1. 王奕嵐。1997。透明質酸還原端氧化衍生物之應用。碩士論文。陽明大學。台灣。台北。 2. 朱兆秀。2005。利用鏈球菌發酵生產透明質酸。化工技術148:165-172。 3. 汪家政、范明。2000。.蛋白質技術手冊。科學出版社。北京。 4. 吳昌至。2002。雞冠與豬眼球中透明質酸和膠原蛋白之抽取及純化。碩士論文。中興大學。台灣。台中。 5. 吳鎮宇。2004。微生物發酵生產透明質酸製程之探討。碩士論文。南台科技大學。台灣。台南。 6. 黃定國。2001。透明質酸之開發與應用。菌種保存及研究簡訊14:1-9。 7. 陳樹人、黃煒智。2004。玻尿酸發酵與分離純化技術。化工技術140:143-151。 8. 蕭至君。2003。利用重組大腸桿菌生產透明質酸之研究。碩士論文。陽明大學。台灣。台北。 9. 謝慧冰。2005。攪拌剪應力是透明質酸發酵放大設計之關鍵因素。碩士論文。成功大學。台灣。台北。 10. Alam, C. A., Seed, M. P. and Willougby, D. A. 1995. Angiostasis and vascular regression in chronic granulomatous inflammation induced by Diclofenac in combination with hyaluronan in mice. J. Pharm. Pharmacol. 47:407-412. 11. Bailey, J. E. and Oilis, D. F. 1986. Biochemical Engineering Fundamentals, 2nd ed., p.721, McGraw-Hill, New York. 12. Balazs, E. A. 1979. Ultrapure hyaluronic acid and the use therefore. US.Pat. 4141973. 13. Balazs, E. A. 1984. Hyaluronic acid:Its structure and use.Cosmetics & Toiletries magazine. 99:65-72. 14. Baker, S. A. and Young, N. M. 1966. Isolation of hyaluronic acid by gel filtration on agarose. Carbohydr. res. 2:363-370. 15. Bell, D. J., Hoare, M. and Dunnill, P. 1983. The Formation of Protein Precipitates and their Centrifugal Recovery. Adv. Biochem. Eng. Biotechnol. 26:1-72 . 16. Bitter, T. and Muir, H. M. 1962. A modified uronic acid carbazole reaction. Anal. Biochem. 4:330 17. Bjurstrom, E. 1985. Biotechnology: Fermentation and Downstream

Processing. Chem. Eng. 92:126-158. 18. Bothner, H., and Wik, O. 1987. Rheology of hyaluronate. Acta Oto-Laryngol. 442:25-30. 19. Brown, M., Marriot, C., and Martin, G. P. 1995. The effect of hyaluronan in the ‘ in vitro ’ deposition of Diclofenac within the skin. Int. J. Tissue React. 17:33-37. 20. Casione, M. 1995. Blends of synthetic and natural polymers as drug delivery systems from growth hormone. Biomaterials. 16:569-576. 21. Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED). 2002. Placenta humana como materia prima farmace utica REGULACION No. 2/2002. 22. Fisher, R. R., Glatz, C. E. and Murphy, P. A. 1986. Effects of Mixing During Acid Addition on Fractionally Precipitated Protein. Biotechnol. Bioeng. 28:1056-1063 . 23. Englard, S. and Seifter, S. 1990. Precipitation Techniques. Meth. Enzymol. 182:285. 24. Fisher, R. R., C. E. Glatz, and P. A. Murphy. 1986. Effects of Mixing During Acid Addition on Fractionally Precipitated Protein. Biotechnol. Bioeng. 28:1056-1063 . 25. Fraser, J. R. E., Laurent, T.C., and Laurent, U.B.G. 1997. Hyaluronan:its nature, distribution, Functions and Turnover, J. Int. Med, 242:27-33. 26. Garcia, A. A., Bonen, M. R., Ramirez-Vick, J., Sadaka, M., and Vuppu, A. 1999. Bioseparation process sciencr. Blackwell Science, Malden, MA 178-229. 27. Hascall, V. C., and Laurent, T. C. 1997. Hyaluronan: Structure and physical properties. http://www.glycoforum.gr.jp. 28. Haxaire, K., Braccini, I., Milas, M., Rinaudo, M., and Pe?rez, S. 2000. Conformational behavior of hyaluronan in relation to its physical properties as probed by molecular modeling. Glycobiology. 10(6):587-594. 29. Hofmeister, F. 1890. Uber die Darstellung von Krystallisirtem Eiralbumin und die Krystallisirbarkeit Colloider Stoffe. Z. Physiol. Chem. 14:165-170. 30. Hollands, I. E., Gomez Barry, H., and Miyares, C. M. 2003. Biological model for test of the photoprotector action from human umbilical cord extract. Revista Cubana de Farmacia. 37(1), 203-208. 31. Iyer, H. V., and Przybycien, T. M. 1994. Protein Precipitation: Effects of Mixing on Protein Solubility. AlChE J. 40(2):349-360. 32. Jamal Alyoussef Alkrad, Yahya Meratani, Reinhard H.H. Neubert. 2002. New approaches for quantifying hyaluronic acid in pharmaceutical semisolid formulations using HPLC and CZE, J. Pharm. Biomed. Anal. 30, 913-919. 33. Johns, M. R., Goh, L. T., and Oeggerli, A. 1994. Effect of pH, agitation and aeration on hyaluronic acid production by Streptococcus zooepidemicus. Biotech. Letter. 16:507-512. 34. Karlsson, G., and Bergman, R. 2003. Determination of the distribution of molecular masses of sodium hyaluronate by high-performance anion exchange chromatography. J. Chromatogr. A 986(1): 67 – 72. 35. Koshiishi I., Takenouchi M., Hasegawa T., and Imanari T. 1998. Enzymatic Method for the Simu taneous Determination of Hyaluron and Chondroitin Sulfates Using High Performance Liquid Chromatography. Anal. Biochem. 265:49-54. 36. Kumar, A., Sahoo, B., Montpetit, A., Behera, S., Lockey R.F., and Mohapatra S.S. 2007. Development of hyluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine: NBM 3: 132-137. 37. Lago, G., Orun~a, L., Cremata, J. A., Pe'rez, C., Coto, G., Lauzan, E., and Kennedy, J.F. 2005. Isolation, purification and characterization of hyaluronan from human umbilical cord residues. Carbohydr Polym. 62:321-326. 38. Laane, C., Boeren, S., Vos, K., and Veeger, C. 1987. Rules for optimization of biocatalysis in organic solvents. Biotechnol. Bioeng. 30: 81-87. 39. Laurent, T. C.. 1987. Biochemistry of jyaluronan. Acta Otolaryngol (Stockh) suppl. 442: 7. 40. Laurent, T. C., and Fraser, J. R. E. 1992. Hyaluronan. FASEB J. 6:2397-2404. 41. Lowry, K. M., and Beavers, E. M. 1994. Thermal stability of sodium hyaluronate in aqueous solution. J. Biomed. Mater. Res. 28:1239. 42. Michaels, A. S., 1990. “ Frontiers of Bioseparations Technology: Unsolved Problems and Novel Process Concepts, ” Int. Conf. on Separations for Biotechnology, UK, 3-8. 43. Moris, J. E., Hoffman, A. S. and Fisher, R. R. 1993. Affinity precipitation of proteins by polyligands. Biotechnol. Bioeng. 41:991-997. 44. Nakayama, A., K. Kawamura, H. Shimada, A. Akaoka, I. Mita, M. Honjo, and Y. Furutani. 1987. Extracellular Production of Human Growth Hormone by Head Portion of the Prepropeptide Derived from Bacillus amyloliquefaciens Neutral Protease in Bacillus subtillis. J. Biotechnol., 5:171-180. 45. Niktari, M., S. Chard, P. Richardson, and M. Hoare. 1990. The Monitoring and Control of protein Purification and Recovery Processes. Int. Conf.on Separations for Biotechnology, UK, p. 622. 46. Nicola , V., and Francesca M. 2003. Purification and characterization of hyaluronic acid from the mollusc bivalve Mytilus galloprovincialis. Biochime. 85:619-625. 47. Nimrod, A. B., Greenman, D., Kanner, M., Landsberg and Beck, Y. 1998. Method of producing high molecular weight sodium hyaluronate byfermentation of Streptococcus. US. Pat. 4780414. 48. Oerther, S., Murin, A. C., Payan, E., Hubert, P., Presle, N., and Dexheimer, J. 2000. High interaction alginate – hyaluronate association by hyaluronate deacetylation for the preparation of efficient biomaterials. Biopolymers. 54(4): 273 – 281. 49. Oerther, S., Payan, E., Lapicque, F., Presle, N., Hubert, I., and Muller, S. 1999. Hyaluronate – alginate combination for the preparation of new biomaterials. Investigation of the behaviour in aqueous solutions. Biochim. Biophys. Acta. 1426(1):85-94. 50. Orvisky, E., Salter, L., Chabrecek, P., Novak, I., Kery, V., and Stancikova, M. 1992. Determination of hyaluronan molecular weight distribution by means of high performance size exclusion chromatography. J. Liq. Chromatogr. 15(18): 3203-3218. 51. Pisa'rc(ik, M., Bakos(, D., and C(eppan, M. 1995. Non-Newtonian properties of hyaluronic acid aqueous solution. Colloids and Surfaces. 97:197-202. 52. Rothstein, F. 1991. Production Scale Issue in Protein Precipitation and Solid/Liquid Separation. Biopharm. Proc., Aster Publishing Corp., Eugene . 53. Schneider, M., Guillot, C. and Lamy, B. 1981 The affinity precipitation technique. Ann. N. Y. Acad. Sci. 369:257-263. 54. Scopes, R. 1982. Protein Purification: Principles and Practice. Springer-Verlag, Berlin. 55. Scott, J. E. 1998. Secondary and tertiary structures of hyaluronan in aqueous solution. Some biological consequences. Glycoforum: Science of Hyaluronan-2. 56. Senstad, C., and Mattiasson, B. 1989. Affinity precipitation using chitosan as ligand carrier. Biotechnol. Bioeng. 33:216-220. 57. Shah, C. B., and Barnett, S. M. 1992. Swelling behavior of hyaluronic acid gels. J. Appl. Polym. Sci. 45:293-298. 58. Smedsrod, B. 1991. Cellular events in the uptake and degradation of hyaluronan. Adv. Drug Deliv. Rev. 7:265. 59. Sunwoo, H. H., Nakano, T., and Sim, J. S. 1998. Isolation and characterization of proteoglycans from growing antlers of wapiti. Comp. Biochem. Physiol. B- Biochem. Mol. Bio. 124(4):437 – 442. 60. Toida, T., and Robert, 1996. Detection of glycosaminoglycans as a copper (II) complex in capillary electrophoresis. J., Electrophoresis.17:341-346. 61. Volpi, N. 2000. Hyaluronic acid and chondroitin sulfate unsaturated disaccharides analysis by high-performance liquid chromatography and fluorimetric detection with dansylhydrazine. Anal. Biochem. 277:19 -24. 62. Watt, J. G. 1970. Automatically controlled

continuous recovery of plasma protein fractions for clinical use. Vox sang. 18:42-61. 63. Weissmann, B., and Meyer, K. 1954. The Structure of hyaluronic acid and of hyaluronic acid from umbilical cord. J. Am. Chem. Soc. 76: 1753-1757.